Abgentil Biomedical

Abgentil Biomedical is a biopharmaceutical company headquartered in Suzhou, China, specializing in the field of targeted protein degradation (TPD). The company leverages a proprietary technology platform to develop next-generation small molecule therapeutics, including molecular glues and Proteolysis Targeting Chimeras (PROTACs), designed to engage E3 ubiquitin ligases for the degradation of disease-relevant proteins. Their primary research focus is directed toward oncology, hematological malignancies, and autoimmune diseases, specifically targeting proteins previously considered 'undruggable.' Supported by major investors such as Lilly Asia Ventures and Qiming Venture Partners, Abgentil is advancing a pipeline of preclinical candidates through lead optimization and IND-enabling studies. The company is led by a team of experienced drug discovery professionals with extensive backgrounds in medicinal chemistry and international pharmaceutical R&D.